Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat

Christos Tikellis1, Peter J Wookey, Riccardo Candido

  • 1Danielle Alberti Memorial Centre for Diabetic Complications, Baker Medical Research Institute, Melbourne, Victoria, Australia.

Diabetes
|March 30, 2004
PubMed

Insights

Blocking the renin-angiotensin system (RAS) with perindopril or irbesartan improved pancreatic islet structure and function in diabetic rats. This suggests a potential mechanism for reducing new-onset diabetes in clinical trials.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • The renin-angiotensin system (RAS) plays a role in the endocrine pancreas.
  • Angiotensin II affects cell proliferation and apoptosis, but its contribution to type 2 diabetes-related islet changes is unclear.

Purpose of the Study:

  • To investigate the specific effects of RAS blockade on islet structure and function in a rat model of type 2 diabetes.

Main Methods:

  • Thirty-six male Zucker diabetic fatty (ZDF) rats were treated for 10 weeks with an angiotensin-converting enzyme inhibitor (perindopril), an angiotensin II receptor blocker (irbesartan), or no treatment.
  • Results were compared to lean littermates (ZL).
  • Islet structure, fibrosis, apoptosis, oxidative stress, and gene expression (transforming growth factor-beta1) were assessed.

Main Results:

  • ZDF rats showed increased intra-islet RAS components, fibrosis, apoptosis, and oxidative stress.
  • Perindopril and irbesartan treatments attenuated disordered islet architecture and diminished islet fibrogenesis.
  • RAS blockade reduced transforming growth factor-beta1 expression and improved first-phase insulin secretion.

Conclusions:

  • RAS blockade improves structural and functional parameters of pancreatic islets in diabetic rats.
  • These findings offer a potential mechanism for the observed reduction in new-onset diabetes in clinical trials involving RAS blockade.

Related Concept Videos